The first real-life multicentre prospective validation study of the electronic chromoendoscopy score (Paddington International Virtual ChromoendoScopy ScOre) and its outcome in ulcerative colitis (2020) Iacucci M, Smith SC, Bazarova A, Shivaji UN, Bhandari P, Cannatelli R, Daperno M, et al. Conference contribution Effectiveness of vedolizumab therapy in a real-world setting in Germany: First results of the VEDOibd study comparing vedolizumab to the use of other biologics (2020) Bokemeyer B, Plachta-Danielzik S, Sobotzki C, Mohl W, Hoffstadt M, Krause T, Atreya R, et al. Conference contribution An IFN-STAT1-MLKL axis drives programmed necrosis of Paneth cells in Crohn's ileitis (2020) Hartmann L, Siegmund B, Weidinger C, Becker C, Neurath M, Günther C Conference contribution Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study (2020) Fischer S, Mesfin SE, Klenske E, Schmitt H, Vitali F, Hirschmann S, Ramming A, et al. Conference contribution Dose-dependent differential effects of vedolizumab therapy on adhesion of regulatory and effector T cells (2020) Becker E, Wiendl M, Schulz-Kuhnt A, Atreya I, Atreya R, Neurath M, Zundler S Conference contribution Addiction in IBD patients: more than just smoke? (2019) Hirschmann S, Koehnen J, Schuster B, Atreya R, Krauss N, Mudter J, Dauer M, et al. Conference contribution Immune profiling of adipose tissue in murine models of inflammatory bowel disease (IBD) (2019) Letizia M, Sillke YR, Schmidt F, Günther C, Kunkel D, Glauben R, Siegmund B, Weidinger C Conference contribution Magnification endoscopy with optical chromoendoscopy for in vivo assessment of histological inflammation in patients with inflammatory bowel disease (2019) Klenske E, Atreya R, Hartmann A, Fischer S, Hirschmann S, Zundler S, Iacucci M, et al. Conference contribution Point of Care detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the biosimilar SB2: performance comparison with ELISA (2019) Atreya R, Schmitt H, Fischer SM, Neurath M, Rekalde X, Nagore D, Ametzazurra A Conference contribution Frequency of B-cell subsets in infliximab-treated paediatric IBD patients (2019) Schnell A, Schwarz B, Wahlbuhl-Becker M, Allabauer I, Rechenauer T, Siebenlist G, Kaspar S, et al. Conference contribution